Michael Lilly to Precursor Cell Lymphoblastic Leukemia-Lymphoma
This is a "connection" page, showing publications Michael Lilly has written about Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Connection Strength
0.457
-
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70.
Score: 0.352
-
Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013 Mar; 27(3):586-94.
Score: 0.105